Naoto Nemoto
CEO
Epsilon Molecular Engineering
Epsilon Molecular Engineering develops high-quality VHH antibodies using a proprietary cDNA display technology combined with the PharmaLogical® Library, enabling rapid screening and selection within 30 business days. This approach eliminates the need for animal immunization, addressing the demand for efficient and ethical antibody development in therapeutic applications.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$8MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- Epsilon Molecular Engineering develops high-quality VHH antibodies using a proprietary cDNA display technology combined with the PharmaLogical® Library, enabling rapid screening and selection within 30 business days. This approach eliminates the need for animal immunization, addressing the demand for efficient and ethical antibody development in therapeutic applications.